Impact Biomedical and Zoar Announce F-4 Effectiveness

Health

Merger Vote
IPO:
Nov 18, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Impact Biomedical and Zoar Limited Announce SEC Effectiveness of Form F-4 and Schedule Merger Vote
HOUSTON, Texas, USA - Impact Biomedical Inc. (NYSE American: IBO) and Zoar Limited announced that the U.S. Securities and Exchange Commission (SEC) declared effective the Form F-4 registration statement on October 23, 2026. This marks a major milestone toward the closing of their proposed business combination involving Impact, Zoar Limited, and Zoar Labs Limited.
... Read on — Members only
About Zoar Ltd
Zoar Limited is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients and orphan drugs and provides contract development and manufacturing services to pharmaceutical and biotechnology companies worldwide. To date, Zoar Limited has shipped more than 85 pharmaceutical products to customers in 35 countries.





















